zoledronic acid and Milk-Alkali Syndrome
zoledronic acid has been researched along with Milk-Alkali Syndrome in 108 studies
Research
Studies (108)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (5.56) | 18.2507 |
2000's | 47 (43.52) | 29.6817 |
2010's | 42 (38.89) | 24.3611 |
2020's | 13 (12.04) | 2.80 |
Authors
Authors | Studies |
---|---|
Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
Chakhtoura, M; El-Hajj Fuleihan, G | 1 |
Berns, JS; Geara, AS; Shulman, R | 1 |
Çakır, Ö; Çizmecioğlu-Jones, FM; Demirsoy, U; Jones, JH; Kilci, F | 1 |
Shane, E; Walker, MD | 1 |
Lopes, MG; McNaught, KA; Morris, JS; Tosi, G | 1 |
Bassatne, A; Drake, MT; El-Hajj Fuleihan, G; Murad, MH; Piggott, T; Rahme, M | 1 |
Carsen, S; Feber, J; Khan, N; Konji, VN; Koujok, K; Molina, MO; Page, M; Rauch, F; Robinson, ME; Seale, E; Sheffield, H; Smit, K; Walker, S; Ward, LM | 1 |
Faiq, S; Hu, T; Ku, G; Lavelle, K; Shoback, D | 1 |
Cao, S; Jin, J; Luo, Y; Shan, X; Wu, H; Wu, Y; Zheng, Z | 1 |
Kushima, C; Nakazato, M; Uchida, T; Yamaguchi, H; Yonekawa, T | 1 |
Elazzazy, S; Hamad, A; Nasser, SM; Sahal, A | 1 |
Colak, U; Hatun, S; Kayserili, H; Mutlu, GY; Sozmen, BO; Yucel, EB | 1 |
Alvarado, M; Bueno, S; González, L; Ramírez, M; Sierra, M | 1 |
Ntanasis-Stathopoulos, I; Terpos, E | 1 |
Ebata, T; Ishiwata, T; Iwasawa, S; Saito, G; Takiguchi, Y; Tatsumi, K; Yoshino, I | 1 |
Eltze, E; Zimmer, V | 1 |
Bansal, B; Farooqui, KJ; Kuchay, MS; Mishra, SK; Mithal, A; Sekhar, L | 1 |
Arase, H; Eriguchi, M; Fujisaki, K; Kitazono, T; Nakamura, M; Nakano, T; Okabe, Y; Tachibana, S; Tomita, K; Tsuruya, K; Yamada, S | 1 |
Peña, S | 1 |
Finazzo, F; Manzoni, P; Militello, MA; Re, MP; Vitaliti, G; Vitaliti, SM | 1 |
Lightowlers, S; Patterson, D | 1 |
Efthymiadou, A; Gkentzi, D; Karana-Ginopoulou, A; Kolyva, S; Varvarigou, A | 1 |
Açıkgöz, Y; Aksoy, S; Ozdemir, NY; Sendur, MA; Uncu, D; Zengin, N | 1 |
Kumar, G; Kumar, N; Sundriyal, D; Walia, M | 1 |
Bezaury, AP; Nevarez-Barragan, MJ; Perez-Diaz, I; Rosas-Jurado, MG; Trejo-Rosales, R | 1 |
Addissie, B; Kumar, R; Martens, P | 1 |
Armanini, D; Bordin, L; Camozzi, V; Donà, G; Iacobone, M; Mian, C; Sabbadin, C | 1 |
Body, JJ; Braun, A; Diel, IJ; Feng, A; Goldwasser, F; Spencer, A; Steger, G; Stopeck, AT; Vadhan-Raj, S; von Moos, R | 1 |
Ananth, CV; Burke, WM; Chen, L; Hershman, DL; Hou, JY; Neugut, AI; Richards, CA; Tergas, AI; Wright, JD | 1 |
Cheung, MS | 1 |
George, S; Hummel, K; Kaplan, P; Levine, MA; Monk, HM; Weber, DR | 1 |
Agarwal, A; Aung, TT; Strand, AO | 1 |
Clark, SL; Nystrom, EM | 1 |
Chang, B; Du, SX; Hu, QX; Li, XD; Lin, FX; Xie, D; Yu, GY; Zheng, GZ | 1 |
Ato, M; Iwagami, M; Kano, S; Ota, N; Seki, T; Yamamoto, K | 1 |
Agosto, S; Ahmadi, S; Bruder, JM; Koops, M; Toro-Tobón, D | 1 |
Carcas, AJ; Cordoba, R; Hernandez-Navarro, F; Lei, SH; Lopez de la Guia, A; Ramirez, E; Sanjurjo, MJ | 1 |
Linneman, T; McMahan, J | 1 |
Alameda Hernando, C; Díaz Guardiola, P; Guijarro de Armas, G; Iglesias Bolaños, P; Pavón de Paz, I; Vega Piñero, B | 1 |
Ericson, S; Gruia, G; Hohneker, J | 1 |
Habib, EE; Sabry, NA | 1 |
Boutrus, R; El-Attar, I; El-Hossieny, H; Kader, YA; Nazmy, M; Zaghloul, MS | 1 |
Civantos Modino, S; Díaz Guardiola, P; Guijarro de Armas, MG; Montaño Martínez, JM; Pavón de Paz, I; Zubieta Tabernero, J | 1 |
Fujikawa, Y; Kadoya, S; Matsumoto, Y; Murakami, N; Murasugi, K; Ohura, F; Tanabe, K; Yoshii, I | 1 |
Argüelles Jiménez, I; Carrillo García, P; García Fernández, H; Quevedo Juanals, J; Serra Soler, G | 1 |
Chiu, CF; Lin, PH; Lu, YS | 1 |
Aksoy, S; Arık, Z; Ozdemir, NY; Sendur, MA; Uncu, D; Yaman, S; Zengin, N | 1 |
Ludwig, H; Zojer, N | 1 |
Imamura, F; Sakai, D; Sugimoto, N; Yagi, T; Yoshinami, T | 1 |
Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 1 |
Bensimon, AG; Ericson, SG; Guo, A; Marynchenko, M; Namjoshi, M; Raje, N; Wu, EQ; Yu, AP | 1 |
Legrand, SB | 1 |
Avgoustidis, N; Ioakeimidis, D; Karageorgas, TP | 1 |
Henk, HJ; Kaura, S | 1 |
Boikos, SA; Hammers, HJ | 1 |
Tao, H; Wang, M; Wang, Y; Wang, Z; Yu, X | 1 |
Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M | 1 |
Major, P | 1 |
Goa, KL; Wellington, K | 1 |
Cook, R; Major, PP | 1 |
Berenson, JR | 2 |
Ashcroft, AJ; Davies, FE; Morgan, GJ | 1 |
Bigos, ST | 1 |
Coleman, RE; Neville-Webbe, Hl | 1 |
Davis, LE; Li, EC | 1 |
Body, JJ | 3 |
Fraser, WD; Mishra, V; Peter, R | 1 |
Bartsch, R; Hussian, D; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
Figgitt, DP; Perry, CM | 1 |
Berenson, J; Hirschberg, R | 1 |
Breay, S | 1 |
Bergner, R; Diel, IJ | 1 |
Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y | 1 |
Khuri, F; Saba, N | 1 |
Rexer, H | 1 |
Barone, A; Foppiani, L; Palummeri, E; Prete, C; Senesi, B; Trasciatti, S; Veneziano, M | 1 |
Balla, J | 1 |
Lugassy, G | 1 |
Etayo-Pérez, A; Garatea-Crelgo, J; Martino-Gorbea, R; Pastor-Zuazaga, D; Sebastián-López, C | 1 |
Suzuki, M; Tomoo, T | 1 |
Bian, SG; Jiang, ZF; Shen, G; Song, ST; Wang, JJ; Wang, YJ; Xie, GR | 1 |
Inoue, K; Iwase, H; Kawazoe, T; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yamamoto, Y; Yoshida, Y | 1 |
Chen, NL; Diaz-Borjon, A; Lim, SS; Seyler, TM | 1 |
Bandeira, F; Colares, V; Griz, L | 1 |
Sakurai, T | 1 |
Barlogie, B; Elici, F; Gokden, N; Kumar, J; Zangari, M | 1 |
Armstrong, A; Branstetter, D; Bussiere, J; Cowan, L; Dougall, WC; Jones, J; Kennedy, B; Miller, RE | 1 |
Maxwell, C | 1 |
Isaia, GC; Pellissetto, C; Ravazzoli, M; Tamone, C | 1 |
Green, JR; Jaeggi, KA; Müller, K | 1 |
Delmas, PD; Lipton, A | 1 |
Delmas, PD | 1 |
Green, J | 1 |
Body, JJ; Ford, J; Lortholary, A; Romieu, G; Vigneron, AM | 1 |
Coleman, RE | 1 |
Abdi, E; Bell, R; Body, J; Hon, J; Lortholary, A; Major, P; Menssen, HD; Mills, G; Quebe-Fehling, E; Seaman, J; Yunus, F | 1 |
Coleman, RE; Major, PP | 1 |
Cheer, SM; Noble, S | 1 |
Lortholary, A | 1 |
Schwetz, BA | 1 |
Davidson, TG | 1 |
Heatley, S | 1 |
Reviews
37 review(s) available for zoledronic acid and Milk-Alkali Syndrome
Article | Year |
---|---|
Treatment of Hypercalcemia of Malignancy.
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Zoledronic Acid | 2021 |
Hypercalcemia: A Review.
Topics: Calcium; Coma; COVID-19; Dehydration; Denosumab; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Immune Checkpoint Inhibitors; Nausea; Neoplasms; Pamidronate; Parathyroid Hormone; SARS-CoV-2; Sleepiness; Sodium Chloride Symporter Inhibitors; Vitamin A; Vitamin D; Vomiting; Zoledronic Acid | 2022 |
Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
Topics: Adult; Cross-Sectional Studies; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Quality of Life; Zoledronic Acid | 2023 |
Controversies in the use of new bone-modifying therapies in multiple myeloma.
Topics: Bone Density Conservation Agents; COVID-19; Denosumab; Diphosphonates; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Receptor Activator of Nuclear Factor-kappa B; Renal Insufficiency; Zoledronic Acid | 2021 |
Hypercalcemia and osteolytic lesions as presenting symptoms of acute lymphoblastic leukemia in childhood. The use of zoledronic acid and review of the literature.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Child; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Zoledronic Acid | 2014 |
Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Calcimimetic Agents; Cinacalcet; Cushing Syndrome; Diphosphonates; Fluid Therapy; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Hyperthyroidism; Imidazoles; Male; Parathyroidectomy; Zoledronic Acid | 2015 |
Drugs Used in Paediatric Bone and Calcium Disorders.
Topics: Acetazolamide; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Calcitriol; Calcium; Child; Denosumab; Diphosphonates; Diuretics; Glucocorticoids; Humans; Hypercalcemia; Hyperphosphatemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Osteoporosis; Parathyroid Hormone; Phosphates; Risedronic Acid; Sodium Potassium Chloride Symporter Inhibitors; Vitamin D; Zoledronic Acid | 2015 |
Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Orthopedic Procedures; Prostatic Neoplasms; Radiotherapy; Spinal Cord Compression; Zoledronic Acid | 2017 |
Chronic Myeloid Leukemia Associated Hypercalcemia: A Case Report and Literature Review.
Topics: Blast Crisis; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Humans; Hypercalcemia; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Zoledronic Acid | 2017 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid | 2011 |
Modern management of malignant hypercalcemia.
Topics: Bone Density Conservation Agents; Calcitonin; Clinical Protocols; Diphosphonates; Fluid Therapy; Gallium; Humans; Hypercalcemia; Imidazoles; Neoplasms; Palliative Care; Pamidronate; Parathyroid Hormone-Related Protein; Zoledronic Acid | 2011 |
Systemic lupus erythematosus and hypercalcaemia: case report and brief review of the literature.
Topics: Adult; Antibodies, Antinuclear; Bone Density Conservation Agents; Diphosphonates; Diuretics; Female; Fluid Therapy; Furosemide; Humans; Hypercalcemia; Imidazoles; Lupus Erythematosus, Systemic; Zoledronic Acid | 2011 |
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2002 |
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Humans; Hypercalcemia; Imidazoles; Kidney; Zoledronic Acid | 2003 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2002 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
Topics: Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Chemokines; Clinical Trials as Topic; Clodronic Acid; Cytokines; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteolysis; Patient Selection; Treatment Outcome; Zoledronic Acid | 2003 |
Selected therapy-related clinical research topics in osteoporosis.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Hip Fractures; Humans; Hypercalcemia; Imidazoles; Injections; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Osteoporosis; Zoledronic Acid | 2003 |
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Topics: Bone Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Matrix Metalloproteinases; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Zoledronic acid: a new parenteral bisphosphonate.
Topics: Animals; Bone Diseases, Metabolic; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Half-Life; Humans; Hypercalcemia; Imidazoles; Metabolic Clearance Rate; Neoplasms; Zoledronic Acid | 2003 |
Hypercalcemia of malignancy.
Topics: Antineoplastic Agents; Diphosphonates; Forecasting; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Parathyroid Hormone-Related Protein; Zoledronic Acid | 2004 |
Zoledronic acid: a review of its use in patients with advanced cancer.
Topics: Area Under Curve; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Drug Tolerance; Economics, Pharmaceutical; Female; Half-Life; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2004 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Multicenter Studies as Topic; Nerve Compression Syndromes; Pain; Spinal Cord Compression; United States; Zoledronic Acid | 2005 |
Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman.
Topics: Aged; Aged, 80 and over; Bone Diseases, Metabolic; Cognition Disorders; Diphosphonates; Disease Progression; Diuretics; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Nervous System Diseases; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2005 |
[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Cells, Cultured; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Geranyltranstransferase; Humans; Hypercalcemia; Imidazoles; Neoplasms; Osteoclasts; Zoledronic Acid | 2005 |
[Treatment of Paget's disease of bone: importance of the zoledronic acid].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Pamidronate; Remission Induction; Treatment Outcome; Zoledronic Acid | 2006 |
[Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Topics: Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoporosis, Postmenopausal; Zoledronic Acid | 2007 |
Clinical research update: zoledronate.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Mice; Multiple Myeloma; Rats; Zoledronic Acid | 1997 |
Current and future directions in medical therapy: hypercalcemia.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2000 |
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2001 |
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Zoledronic Acid | 2001 |
Zoledronic acid.
Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Neoplasms; Zoledronic Acid | 2001 |
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematologic Neoplasms; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Prognosis; Recurrence; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2001 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2001 |
Conventional treatment of hypercalcemia of malignancy.
Topics: Calcitonin; Clinical Protocols; Diphosphonates; Drug Costs; Fluid Therapy; Gallium; Humans; Hydrocortisone; Hypercalcemia; Imidazoles; Neoplasms; Nucleic Acid Synthesis Inhibitors; Plicamycin; Prednisone; Rehydration Solutions; Zoledronic Acid | 2001 |
Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pain; Zoledronic Acid | 2001 |
Trials
9 trial(s) available for zoledronic acid and Milk-Alkali Syndrome
Article | Year |
---|---|
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proportional Hazards Models; Zoledronic Acid | 2015 |
Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Young Adult; Zoledronic Acid | 2011 |
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Egypt; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pain; Placebo Effect; Prospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Diphosphonates; Europe; Fractures, Bone; Health Care Costs; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Spinal Cord Compression; Zoledronic Acid | 2011 |
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Spinal Cord Compression; Strontium; Zoledronic Acid | 2013 |
A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Treatment Outcome; Zoledronic Acid | 2005 |
[Use of zoledronic acid for high risk prostate cancer patients].
Topics: Animals; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Europe; Humans; Hypercalcemia; Imidazoles; Injections, Intravenous; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2005 |
A dose-finding study of zoledronate in hypercalcemic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid | 1999 |
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Zoledronic Acid | 2001 |
Other Studies
63 other study(ies) available for zoledronic acid and Milk-Alkali Syndrome
Article | Year |
---|---|
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia.
Topics: Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2022 |
Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Topics: Adolescent; Bone Density Conservation Agents; Calcium; Child; Denosumab; Diphosphonates; Hormones, Ectopic; Humans; Hypercalcemia; Male; Parathyroid Hormone; Rhabdomyosarcoma; Zoledronic Acid | 2022 |
Retrospective assessment of tolerability and efficacy of zoledronate in the palliative treatment of cancer-bearing dogs.
Topics: Animals; Calcium; Dog Diseases; Dogs; Hypercalcemia; Neoplasms; Pain; Palliative Care; Retrospective Studies; Zoledronic Acid | 2023 |
Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI.
Topics: Bone Density; Bone Density Conservation Agents; Calcium; Child; Denosumab; Humans; Hypercalcemia; Male; Osteogenesis Imperfecta; Zoledronic Acid | 2023 |
Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.
Topics: Calcium; Cinacalcet; Humans; Hypercalcemia; Male; Middle Aged; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Zoledronic Acid | 2023 |
Successful treatment of hypercalcemia in a Chinese patient with a novel homozygous mutation in the CYP24A1 gene using zoledronic acid: a case report.
Topics: Calcium; East Asian People; Female; Humans; Hypercalcemia; Infant; Mutation; Vitamin D3 24-Hydroxylase; Zoledronic Acid | 2023 |
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Topics: Ankle; Anorexia; Antithyroid Agents; Aromatase Inhibitors; Arthralgia; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen Type I; Denosumab; Deprescriptions; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Graves Disease; Humans; Hypercalcemia; Methimazole; Middle Aged; Parathyroid Hormone; Peptides; Potassium Iodide; Radionuclide Imaging; Tartrate-Resistant Acid Phosphatase; Thirst; Zoledronic Acid | 2020 |
Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cohort Studies; Denosumab; Female; Humans; Hypercalcemia; Hypocalcemia; Incidence; Male; Middle Aged; Retrospective Studies; Zoledronic Acid | 2019 |
Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
Topics: Bone Density Conservation Agents; Calcitriol; Carcinoma, Squamous Cell; Child, Preschool; Humans; Hypercalcemia; Male; Paraneoplastic Syndromes; Prognosis; Xeroderma Pigmentosum; Zoledronic Acid | 2019 |
Hypercalcemia of Malignancy in a Patient with Hypoparathyroidism: A Complicated but Treatable Condition.
Topics: Bone Density Conservation Agents; Calcitriol; Diphosphonates; Eye Neoplasms; Humans; Hypercalcemia; Hypoparathyroidism; Male; Melanoma; Middle Aged; Noonan Syndrome; Zoledronic Acid | 2019 |
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2021 |
Parathyroid Hormone-Related Peptide (PTHrp)-Secreting Liver Metastatic Large-Cell Neuroendocrine Carcinoma of the Sigmoid Colon.
Topics: Aged; Biopsy; Bone Density Conservation Agents; Carcinoma, Neuroendocrine; Colon, Sigmoid; Colonic Neoplasms; Colonoscopy; Humans; Hypercalcemia; Liver Neoplasms; Male; Neoplasm Grading; Neoplasm Staging; Paraneoplastic Syndromes; Parathyroid Hormone-Related Protein; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2021 |
Glucocorticoid sparing effect of zoledronic acid in sarcoid hypercalcemia.
Topics: Administration, Oral; Adult; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Middle Aged; Sarcoidosis; Zoledronic Acid | 2017 |
Immobilization-induced severe hypercalcaemia successfully treated with reduced dose of zoledronate in a maintenance haemodialysis patient.
Topics: Adult; Bed Rest; Bedridden Persons; Biomarkers; Bone Density Conservation Agents; Calcium; Humans; Hypercalcemia; Male; Renal Dialysis; Severity of Illness Index; Treatment Outcome; Up-Regulation; Zoledronic Acid | 2018 |
What is causing this patient's hypercalcemia?
Topics: Abdominal Pain; Diagnosis, Differential; Fatal Outcome; Female; Humans; Hypercalcemia; Middle Aged; Neoplasms, Unknown Primary; Psychotherapy, Brief; Sodium Chloride; Tomography, X-Ray Computed; Zoledronic Acid | 2019 |
Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia.
Topics: Bone Density Conservation Agents; Calcium; Drug Resistance; Fat Necrosis; Female; Furosemide; Glucocorticoids; Humans; Hypercalcemia; Infant, Newborn; Methylprednisolone; Sodium Potassium Chloride Symporter Inhibitors; Subcutaneous Fat; Term Birth; Zoledronic Acid | 2019 |
Mismanagement of malignant hypercalcaemia.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Malpractice; Neoplasms; Zoledronic Acid | 2013 |
Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia.
Topics: Ameloblastoma; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Mandibular Neoplasms; Middle Aged; Polydipsia; Polyuria; Treatment Refusal; Zoledronic Acid | 2014 |
Livedo reticularis heralding hypercalcaemia of malignancy.
Topics: Calcitonin; Carcinoma, Squamous Cell; Diphosphonates; Diuretics; Fluid Therapy; Follow-Up Studies; Humans; Hypercalcemia; Imidazoles; Livedo Reticularis; Male; Middle Aged; Monitoring, Physiologic; Mouth Neoplasms; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2014 |
Rare association between penile squamous cell carcinoma and parathyroid related peptide (PTH-rP) secretion.
Topics: Bone Density Conservation Agents; Carcinoma, Squamous Cell; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Parathyroid Hormone; Pelvis; Penile Neoplasms; Rare Diseases; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Follicular lymphoma presenting with hypercalcaemia: an unusual mechanism of hypercalcaemia.
Topics: Aged; Bone Density Conservation Agents; Calcitonin; Chemokines; Cytokines; Diphosphonates; Diuretics; Female; Furosemide; Humans; Hypercalcemia; Imidazoles; Lymphoma, Follicular; Neoplasm Staging; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Parotid Gland; Positron-Emission Tomography; Sentinel Lymph Node Biopsy; Sodium Chloride; Vitamin D; Zoledronic Acid | 2015 |
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Topics: Aged; Bone Neoplasms; Calcitonin; Diphosphonates; Diuretics; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pamidronate; Quality of Health Care; Treatment Outcome; Zoledronic Acid | 2015 |
Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
Topics: Acute-Phase Reaction; Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Diseases; Calcitriol; Calcium; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Osteoporosis; Prospective Studies; Retrospective Studies; Risk Factors; Young Adult; Zoledronic Acid | 2015 |
Not all ST-segment changes are myocardial injury: hypercalcaemia-induced ST-segment elevation.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Brugada Syndrome; Cardiac Conduction System Disease; Diagnosis, Differential; Diphosphonates; Diuretics; Echocardiography; Electrocardiography; Follow-Up Studies; Furosemide; Humans; Hypercalcemia; Imidazoles; Male; Multiple Myeloma; Myocardial Ischemia; Point-of-Care Testing; Treatment Outcome; Zoledronic Acid | 2015 |
A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Hypercalcemia; Hypophosphatemia; Imidazoles; Male; Middle Aged; Paraneoplastic Syndromes; Zoledronic Acid | 2016 |
Dual antiplasmodial activity of vitamin D3 and its analog, 22-oxacalcitriol, by direct and indirect mechanisms.
Topics: Acute Disease; Animals; Antimalarials; Body Weight; Calcitriol; Cholecalciferol; Chronic Disease; Diphosphonates; Erythrocytes; Humans; Hypercalcemia; Imidazoles; Interferon-gamma; Malaria; Mice; Mice, Inbred BALB C; Mice, Knockout; Parasitemia; Plasmodium chabaudi; Receptors, Calcitriol; Zoledronic Acid | 2017 |
Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid.
Topics: Adult; Antineoplastic Agents; Diphosphonates; Drug Interactions; Drug Therapy, Combination; Humans; Hypercalcemia; Imidazoles; Itraconazole; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin; Zoledronic Acid | 2008 |
A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Calcitonin; Carcinoma, Transitional Cell; Crystalloid Solutions; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Isotonic Solutions; Male; Neoplasm Metastasis; Pamidronate; Ureteral Neoplasms; Zoledronic Acid | 2009 |
[Primary hyperparathyroidism. An alternative to the surgery].
Topics: Adenoma; Aged, 80 and over; Breast Neoplasms; Carcinoma; Carcinoma, Renal Cell; Cinacalcet; Comorbidity; Contraindications; Diphosphonates; Drug Therapy, Combination; Female; Fluid Therapy; Furosemide; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Imidazoles; Kidney Function Tests; Kidney Neoplasms; Naphthalenes; Parathyroid Neoplasms; Parathyroidectomy; Treatment Refusal; Zoledronic Acid | 2009 |
FDA drug information that never reaches clinicians.
Topics: Diphosphonates; Drug Approval; Drug Industry; Drug Labeling; Humans; Hypercalcemia; Imidazoles; Kidney Diseases; United States; United States Food and Drug Administration; Zoledronic Acid | 2010 |
[Primary hyperparathyroidism in a patient with Paget's bone disease].
Topics: Adenoma; Aged; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Osteitis Deformans; Osteoporosis; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Radionuclide Imaging; Zoledronic Acid | 2010 |
[A case report of a patient treatable by home palliative care, administered zoledronic acid used for bladder cancer with hypercalcemia].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Fatal Outcome; Female; Home Care Services; Humans; Hypercalcemia; Imidazoles; Palliative Care; Terminal Care; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
[Parathyroid crisis due to a cystic parathyroid adenoma].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Colectomy; Colonic Diseases; Consciousness Disorders; Cysts; Diagnostic Imaging; Diphosphonates; Emergencies; Female; Furosemide; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Imidazoles; Intestinal Perforation; Kidney Calculi; Middle Aged; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Thyroidectomy; Zoledronic Acid | 2011 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Diphosphonates; Female; Fluorouracil; Humans; Hypercalcemia; Imidazoles; Leucovorin; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure; Vinblastine; Vinorelbine; Zoledronic Acid | 2011 |
Small cell carcinoma of the urinary bladder with hypercalcemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Small Cell; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Zoledronic Acid | 2012 |
A case of acquired Fanconi syndrome induced by zoledronic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Fanconi Syndrome; Female; Humans; Hypercalcemia; Imidazoles; Kidney Function Tests; Middle Aged; Zoledronic Acid | 2011 |
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Comorbidity; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2011 |
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Insurance Claim Review; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Spinal Cord Compression; United States; Zoledronic Acid | 2012 |
Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Carcinoma, Renal Cell; Denosumab; Diphosphonates; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hypercalcemia; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Parathyroid Hormone; Risk Assessment; Zoledronic Acid | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cancer Care Facilities; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Middle Aged; Pamidronate; Registries; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2013 |
Severe hypocalcaemia after being given intravenous bisphosphonate.
Topics: Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid | 2004 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Imidazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Pamidronate; Quality of Life; Recurrence; Zoledronic Acid | 2004 |
Hypocalcaemia after intravenous bisphosphonate: read the product information first.
Topics: Diphosphonates; Drug Labeling; Humans; Hypercalcemia; Hypocalcemia; Imidazoles; Infusions, Intravenous; Zoledronic Acid | 2004 |
Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Bone Neoplasms; Creatinine; Diphosphonates; Half-Life; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Kidney; Safety; Zoledronic Acid | 2005 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid | 2006 |
[Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Safety; Zoledronic Acid | 2005 |
[Two cases of stage IV breast cancer with severe hypercalcemia].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Goserelin; Humans; Hypercalcemia; Imidazoles; Leuprolide; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Quality of Life; Tamoxifen; Zoledronic Acid | 2006 |
Bisphosphonate-associated arthritis.
Topics: Arthritis; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Zoledronic Acid | 2006 |
Potential effect of zoledronate therapy in heavy proteinuria.
Topics: Biopsy; Bone Density Conservation Agents; Diphosphonates; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Middle Aged; Multiple Myeloma; Prednisone; Proteinuria; Zoledronic Acid | 2007 |
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Topics: Animals; Bone Resorption; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Immunologic; Female; Hydroxycholecalciferols; Hypercalcemia; Imidazoles; Immunity, Innate; Immunoglobulin G; Influenza A Virus, H3N2 Subtype; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Fusion Proteins; Zoledronic Acid | 2007 |
Role of the nurse in preserving patients' independence.
Topics: Activities of Daily Living; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Documentation; Drug Monitoring; Humans; Hypercalcemia; Imidazoles; Nurse's Role; Nursing Assessment; Nursing Records; Oncology Nursing; Pain; Patient Compliance; Patient Education as Topic; Social Support; Treatment Outcome; Zoledronic Acid | 2007 |
Acute adrenal crisis and hypercalcemia in a patient assuming high liquorice doses.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adrenalectomy; Alkalosis; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diphosphonates; Female; Glycyrrhiza; Humans; Hydrocortisone; Hyperaldosteronism; Hypercalcemia; Hypernatremia; Hypokalemia; Imidazoles; Middle Aged; Zoledronic Acid | 2008 |
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Drug Evaluation, Preclinical; Hypercalcemia; Imidazoles; Interleukin-1; Male; Mice; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Parathyroidectomy; Peptide Fragments; Proteins; Rats; Thyroidectomy; Zoledronic Acid | 1994 |
Pamidronate (Aredia) and zoledronate: update on clinical results. Introduction.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Organophosphorus Compounds; Osteoblasts; Pamidronate; Zoledronic Acid | 1996 |
Zoledronate.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteitis Deformans; Osteoporosis; Zoledronic Acid | 1996 |
Zoledronate: the preclinical pharmacology.
Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Animal; Female; Hypercalcemia; Imidazoles; Ovariectomy; Pamidronate; Parathyroidectomy; Rats; Thyroidectomy; Zoledronic Acid | 1996 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2000 |
From the Food and Drug Administration.
Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Diphosphonates; Equipment Reuse; Heart Failure; Humans; Hypercalcemia; Imidazoles; Natriuretic Peptide, Brain; Neoplasms; United States; United States Food and Drug Administration; Zoledronic Acid | 2001 |
New bisphosphonic acid approved by FDA.
Topics: Diphosphonates; Drug Approval; Humans; Hypercalcemia; Imidazoles; Neoplasm Proteins; Neoplasms; Parathyroid Hormone-Related Protein; United States; United States Food and Drug Administration; Zoledronic Acid | 2001 |